Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

3.6%

5 terminated/withdrawn out of 138 trials

Success Rate

91.8%

+5.3% vs industry average

Late-Stage Pipeline

35%

48 trials in Phase 3/4

Results Transparency

73%

41 of 56 completed trials have results

Key Signals

38 recruiting41 with results

Enrollment Performance

Analytics

Phase 2

55(41.7%)

Phase 3

48(36.4%)

N/A

15(11.4%)

Phase 1

13(9.8%)

Early Phase 1

1(0.8%)

132Total

Phase 2(55)

Phase 3(48)

N/A(15)

Phase 1(13)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (138)

Showing 20 of 138 trials

NCT07390435Recruiting

Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials

Role: lead

NCT05371808Recruiting

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

Role: lead

NCT04136353Phase 3Active Not Recruiting

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Role: collaborator

NCT05640999Phase 2Recruiting

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Role: lead

NCT03055013Phase 3Active Not Recruiting

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Role: collaborator

NCT03914612Phase 3Active Not Recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Role: collaborator

NCT02003222Phase 3Active Not Recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Role: collaborator

NCT03233711Phase 3Active Not Recruiting

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Role: collaborator

NCT02502266Phase 2Active Not Recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Role: collaborator

NCT00819208Not ApplicableCompleted

Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Role: lead

NCT02960087Not ApplicableActive Not Recruiting

Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

Role: lead

NCT07152821Phase 3Recruiting

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

Role: lead

NCT02436707Phase 2Active Not Recruiting

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Role: lead

NCT06439225Phase 3Recruiting

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Role: lead

NCT06235697Phase 3Recruiting

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Role: lead

NCT06686771Phase 3Recruiting

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Role: lead

NCT05998642Phase 2Recruiting

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Role: lead

NCT06358469Not ApplicableRecruiting

STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision

Role: lead

NCT06592924Phase 3Recruiting

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Role: lead

NCT02821013Phase 3Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Role: lead